Maher Dermot P, Serna-Gallegos Derek, Mardirosian Rodney, Thomas Otto J, Zhang Xiao, McKenna Robert, Yumul Roya, Zhang Vida
Harvard Medical School, Department of Anesthesia, Massachusetts General Hospital, Boston, MA USA.
Department of Anesthesia, Cedars Sinai Medical Center, Los Angeles, CA.
Pain Med. 2017 Jun 1;18(6):1152-1160. doi: 10.1093/pm/pnw149.
The use of multiple-level, single-injection intercostal nerve blocks for pain control following video-assisted thorascopic surgery (VATS) is limited by the analgesic duration of local anesthetics. This study examines whether the combination of perineural and intravenous (IV) dexamethasone will prolong the duration of intraoperatively placed intercostal nerve blocks following VATS compared with IV dexamethasone and a perineural saline placebo.
Prospective, double-blind, randomized placebo-controlled trial.
Single level-1 academic trauma center.
Forty patients undergoing a unilateral VATS under the care of a single surgeon.
Patients were randomly assigned to two groups and received an intercostal nerve block containing 1) 0.5% bupivacaine with epinephrine and 1 ml of 0.9% saline or 2) 0.5% bupivacaine with epinephrine and 1 ml of a 4 mg/ml dexamethasone solution. All patients received 8 mg of IV dexamethasone.
Group 2 had lower NRS-11 scores at post-operative hours 8 (5.05, SD = 2.13 vs 3.50, SD = 2.50; p = 0.04), 20 (4.30, SD = 2.96 vs 2.26, SD = 2.31; p = 0.02), and 24 (4.53, SD = 1.95 vs 2.26, SD = 2.31; p = 0.02). Equianalgesic opioid requirement was decreased in group 2 at 32 hours (5.78 mg, SD = 5.77 vs 1.67 mg, SD = 3.49; p = 0.02). Group 2 also had greater FEV1 measured at 8, 12, 24, and 44 hours; greater FVC at 24 hours; greater PEF at 28 through 48 hours; and greater FEV1/FVC at 8 and 36 hours.
The combination of IV and perineural dexamethasone prolonged the duration of a single-injection bupivacaine intercostal nerve block as measured by NRS-11 compared with IV dexamethasone alone at 24 hours. Reduced NRS-11 at other times, reduced opioid requirements, and increased PFTs were observed in group 2.
在电视辅助胸腔镜手术(VATS)后,用于疼痛控制的多级单次注射肋间神经阻滞受局部麻醉药镇痛持续时间的限制。本研究旨在探讨与静脉注射地塞米松和神经周围生理盐水安慰剂相比,神经周围和静脉注射(IV)地塞米松联合使用是否会延长VATS术中放置的肋间神经阻滞的持续时间。
前瞻性、双盲、随机安慰剂对照试验。
单一的一级学术创伤中心。
40例在单一外科医生护理下接受单侧VATS的患者。
患者被随机分为两组,接受包含以下成分的肋间神经阻滞:1)含肾上腺素的0.5%布比卡因和1毫升0.9%生理盐水,或2)含肾上腺素的0.5%布比卡因和1毫升4毫克/毫升地塞米松溶液。所有患者均接受8毫克静脉注射地塞米松。
第2组在术后8小时(5.05,标准差=2.13对3.50,标准差=2.50;p=0.04)、20小时(4.30,标准差=2.96对2.26,标准差=2.31;p=0.02)和24小时(4.53,标准差=1.95对2.26,标准差=2.31;p=0.02)时的数字疼痛评分量表-11(NRS-11)得分较低。第2组在32小时时的等效镇痛阿片类药物需求量降低(5.78毫克,标准差=5.77对1.67毫克,标准差=3.49;p=0.02)。第2组在8、12、24和44小时时测量的第1秒用力呼气量(FEV1)也更高;在24小时时用力肺活量(FVC)更高;在28至48小时时最大呼气流量(PEF)更高;在8和36小时时FEV1/FVC更高。
与仅静脉注射地塞米松相比,静脉注射和神经周围注射地塞米松联合使用在24小时时延长了单次注射布比卡因肋间神经阻滞的持续时间,这通过NRS-11测量得出。在第2组中观察到其他时间点NRS-11降低、阿片类药物需求量减少以及肺功能测试指标增加。